What is the recommended management for a woman with recurrent vulvovaginal candidiasis (≥ four symptomatic episodes in the past 12 months)?

Recurrent Vulvovaginal Candidiasis Treatment

For recurrent vulvovaginal candidiasis (≥3-4 episodes per year), initiate an induction phase with fluconazole 150 mg every 72 hours for 3 doses, followed by maintenance therapy with fluconazole 150 mg weekly for 6 months. 1

Definition and Diagnostic Confirmation

Recurrent VVC (RVVC) is now defined as ≥3 symptomatic episodes over 12 months (updated from the previous definition of ≥4 episodes) 1. Before initiating long-term therapy:

• Confirm diagnosis with culture or PCR testing to identify Candida species and rule out non-albicans species that may require alternative management 1
• PCR demonstrates superior sensitivity (90.9%) and specificity (94.1%) compared to microscopy 1
• Consider testing at vaginal pH 4 (not laboratory standard pH 7) as antifungal MICs are significantly higher at physiologic vaginal pH, particularly for C. glabrata with terconazole (388-fold difference) 1

Standard Treatment Protocol

Induction Phase

• Fluconazole 150 mg orally every 72 hours for 3 doses to achieve initial clinical remission 1

Maintenance Phase

• Fluconazole 150 mg orally once weekly for 6 months 1, 2, 3
• This regimen achieves 90.8% disease-free rate at 6 months (vs. 35.9% placebo) and extends median time to recurrence to 10.2 months (vs. 4.0 months placebo) 3
• Quality of life improves in 96% of women on maintenance therapy 1

Critical caveat: Recurrence after completing maintenance therapy is common—over 63% of women experience ongoing infections after stopping treatment, with only 42.9% remaining disease-free at 12 months 1, 3. This is suppressive, not curative therapy.

Alternative and Rescue Therapies

When fluconazole maintenance fails or is contraindicated:

For Azole-Resistant or Refractory Cases

Vaginal boric acid 600 mg suppositories daily for 14-21 days is the most practical alternative 4. This represents the cheapest and easiest option when first-line therapy fails.

Novel FDA-Approved Agents

• Oteseconazole (VT-1161): Highly-selective CYP51 inhibitor with very long half-life. In RCTs, 12-24 weeks of treatment achieved only 4% recurrence at 48 weeks vs. 52% placebo 1—dramatically superior to fluconazole maintenance
• Ibrexafungerp: Alternative for azole-resistant cases 5, 6

Topical Maintenance Options

Evidence is very uncertain regarding oral vs. topical maintenance therapy 7. A 2026 meta-analysis of 6 trials (1,224 participants) found no significant difference between oral fluconazole and topical azoles (clotrimazole, fenticonazole, nystatin) for recurrence, satisfaction, or adverse events, but the evidence quality was very low due to high bias risk and imprecision 7.

If choosing topical therapy despite uncertain evidence:

• Clotrimazole vaginal suppositories weekly
• Recognize that longer courses may be needed for symptom resolution 2

Species-Specific Considerations

Non-albicans Candida (especially C. glabrata)

• Requires longer treatment duration 5
• Consider non-azole alternatives earlier due to intrinsically higher azole MICs at vaginal pH 1
• Boric acid or newer agents (oteseconazole, ibrexafungerp) preferred 4, 5, 6

Monitoring and Follow-Up

• No routine test of cure needed if symptoms resolve 2
• If symptoms persist or recur during maintenance:
  • Repeat culture with antifungal susceptibility testing
  • Verify compliance with weekly dosing
  • Consider alternative diagnoses: desquamative inflammatory vaginitis, genitourinary syndrome of menopause, vulvodynia 4
  • Evaluate for unrecognized resistance (test at pH 4 if possible) 1

Emerging Therapies (Not Yet Standard)

The following show promise but lack sufficient evidence for routine recommendation:

• Probiotics (particularly Lactobacillus crispatus): Not currently recommended for VVC prevention 4, 5
• Immunotherapeutic vaccines (NDV-3A) 5
• Designed antimicrobial peptides 5
• Biofilm-disrupting agents 6

Common Pitfalls

1. Treating empirically without culture confirmation—non-albicans species require different approaches
2. Using standard laboratory susceptibility testing at pH 7—clinically relevant resistance may be missed at physiologic vaginal pH 4 1
3. Stopping maintenance therapy too early—6 months is the evidence-based duration 3
4. Expecting cure rather than suppression—counsel patients that recurrence after stopping therapy is common and does not represent treatment failure 1, 3
5. Not considering alternative diagnoses when treatment fails 4